IN8bio, Inc. (INAB)
1.10
-0.04
(-3.51%)
USD |
NASDAQ |
Sep 09, 14:38
IN8bio Enterprise Value : -4.546M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -4.546M |
| September 04, 2026 | -3.955M |
| September 03, 2026 | -4.349M |
| September 02, 2026 | -4.941M |
| September 01, 2026 | -5.039M |
| August 31, 2026 | -4.941M |
| August 28, 2026 | -5.581M |
| August 27, 2026 | -5.532M |
| August 26, 2026 | -4.103M |
| August 25, 2026 | -4.251M |
| August 24, 2026 | -4.152M |
| August 21, 2026 | -3.167M |
| August 20, 2026 | -3.857M |
| August 19, 2026 | -3.955M |
| August 18, 2026 | -4.546M |
| August 17, 2026 | -4.842M |
| August 14, 2026 | -4.941M |
| August 13, 2026 | -4.152M |
| August 12, 2026 | -5.941M |
| August 11, 2026 | -5.433M |
| August 10, 2026 | -6.163M |
| August 07, 2026 | -6.137M |
| August 06, 2026 | -6.222M |
| August 05, 2026 | -6.036M |
| August 04, 2026 | -6.319M |
| Date | Value |
|---|---|
| August 03, 2026 | -6.32M |
| July 31, 2026 | -5.581M |
| July 30, 2026 | -5.138M |
| July 29, 2026 | -5.236M |
| July 28, 2026 | -4.842M |
| July 27, 2026 | -4.054M |
| July 24, 2026 | -3.955M |
| July 23, 2026 | -4.054M |
| July 22, 2026 | -3.660M |
| July 21, 2026 | -3.561M |
| July 20, 2026 | -3.364M |
| July 17, 2026 | -2.674M |
| July 16, 2026 | -2.182M |
| July 15, 2026 | -1.590M |
| July 14, 2026 | -2.182M |
| July 13, 2026 | -2.576M |
| July 10, 2026 | -2.674M |
| July 09, 2026 | -1.985M |
| July 08, 2026 | -2.182M |
| July 07, 2026 | -2.083M |
| July 06, 2026 | -1.590M |
| July 02, 2026 | -1.788M |
| July 01, 2026 | -1.788M |
| June 30, 2026 | -1.886M |
| June 29, 2026 | -5.506M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.781M |
| Total Expenses (Quarterly) | 4.781M |
| EPS Diluted (Quarterly) | -0.2456 |
| Earnings Yield | -169.3% |
| Normalized Earnings Yield | -169.31 |